# IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

SOUTH SAN FRANCISCO, Calif., July 29, 2024 / PRNewswire / -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event.

## 2024 BTIG Virtual Biotechnology Conference

Monday, August 5th, 2024 at 10:00 AM ET

 Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst

A live audio webcast of the conference event will be available through the conference host.

#### **About IDEAYA Biosciences**

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

## **Forward-Looking Statements**

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 20, 2024.

### **Investor and Media Contact**

**IDEAYA Biosciences** 

Andres Ruiz Briseno

Senior Vice President, Head of Finance and Investor Relations

investor@ideayabio.com

SOURCE IDEAYA Biosciences, Inc.